1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Allergies – Pipeline Review, H1 2013

Allergies – Pipeline Review, H1 2013

  • February 2013
  • -
  • Global Markets Direct
  • -
  • 293 pages

Allergies – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Allergies - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Allergies, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Allergies. Allergies - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Allergies.
- A review of the Allergies products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Allergies pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Allergies.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Allergies pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Allergies - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Allergies Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Allergies 11
Allergies Therapeutics under Development by Companies 13
Allergies Therapeutics under Investigation by Universities/Institutes 19
Late Stage Products 20
Comparative Analysis 20
Mid Clinical Stage Products 21
Comparative Analysis 21
Early Clinical Stage Products 22
Comparative Analysis 22
Discovery and Pre-Clinical Stage Products 23
Comparative Analysis 23
Allergies Therapeutics - Products under Development by Companies 24
Allergies Therapeutics - Products under Investigation by Universities/Institutes 32
Companies Involved in Allergies Therapeutics Development 33
Alcon, Inc. 33
Shionogi and Co., Ltd. 34
AstraZeneca PLC 35
GlaxoSmithKline plc 36
Biotec Pharmacon ASA 37
Merck and Co., Inc. 38
AbGenomics International, Inc. 39
United Biomedical, Inc. 40
Dainippon Sumitomo Pharma Co., Ltd. 41
Pharming Group N.V. 42
BioLineRx, Ltd. 43
Novartis AG 44
Actelion Ltd 45
ALK-Abello A/S 46
Dyax Corp. 47
Japan Tobacco Inc. 48
Taiho Pharmaceutical Co., Ltd. 49
ViroPharma Incorporated 50
Shire Plc 51
DBV Technologies 52
Celldex Therapeutics, Inc. 53
Allergy Therapeutics plc 54
IntelGenx Technologies Corp. 55
Idera Pharmaceuticals, Inc. 56
Elite Pharmaceuticals, Inc. 57
BioCryst Pharmaceuticals, Inc. 58
NeoStem, Inc. 59
Pharmacyclics, Inc. 60
Stallergenes S.A. 61
Torii Pharmaceutical Co., Ltd. 62
Hanall Pharmaceutical Co., Ltd. 63
Cytos Biotechnology AG 64
Sirion Therapeutics, Inc. 65
Proteo, Inc. 66
University of Erlangen-Nurnberg 67
Antigen Express, Inc. 68
Marinomed Biotechnologie GmbH 69
ActogeniX NV 70
Allergopharma Joachim Ganzer KG 71
Immupharma Plc 72
7TM Pharma A/S 73
Circassia Holdings Ltd. 74
Oxagen Limited 75
EpiVax, Inc. 76
Indus Biotech Private Limited 77
Vantia Therapeutics 78
Monosol Rx, LLC 79
Xencor, Inc. 80
Immune Design Inc. 81
iBio, Inc. 82
Tris Pharma, Inc. 83
Laboratorios LETI S.L. 84
ANERGIS SA 85
SuppreMol GmbH 86
Viromed Co., Ltd. 87
SIFI Pharma 88
REGiMMUNE Corporation 89
Immunomic Therapeutics, Inc. 90
Bial - Portela and Ca, S.A. 91
Interprotein Corporation 92
ImmunoFrontier, Inc. 93
Biomay AG 94
Vaxine Pty Ltd 95
RaQualia Pharma Inc. 96
ToleroTech Inc. 97
Immune Technologies and Medicine 98
Allergies - Therapeutics Assessment 99
Assessment by Monotherapy Products 99
Assessment by Combination Products 100
Drug Profiles 101
IMO-2134 - Drug Profile 101
PCI-45261 - Drug Profile 102
TM-30510 - Drug Profile 103
icatibant acetate - Drug Profile 104
Pollinex Quattro Japanese Cedar - Drug Profile 106
MPL-Based Allergy Vaccine - Drug Profile 107
Pollinex Quattro Tree - Drug Profile 109
MATA MPL - Drug Profile 111
Pollinex Quattro Grass - Drug Profile 113
conestat alfa - Drug Profile 114
AM-461 - Drug Profile 116
ActoBiotics For Allergic Disease - Drug Profile 117
Norketotifen - Drug Profile 118
INDUS-82010 - Drug Profile 119
Leech-Derived Protein Inhibitor - Drug Profile 120
PKal Inhibitor - Drug Profile 121
Allergen Extract Of Phleum Pratense - Drug Profile 122
S-555739 - Drug Profile 123
AM-211 - Drug Profile 125
Birch Pollen Allergoid - Drug Profile 127
ToleroMune Ragweed Allergy T-cell Vaccine - Drug Profile 128
SF-107 - Drug Profile 130
IgE Inhibitor - Drug Profile 131
Zinc Chelators - Drug Profile 132
Soluble Beta Glucan - Drug Profile 133
HL-025 - Drug Profile 136
MK-8237 - Drug Profile 137
ToleroMune Grass Allergy T-cell Vaccine - Drug Profile 138
ToleroMune Cat Allergy T Cell Vaccine - Drug Profile 140
MK-7243 - Drug Profile 142
Phleum Pratense - Drug Profile 143
MK-3641 - Drug Profile 144
AL-0206st - Drug Profile 146
IPP-201007 - Drug Profile 147
ViaSkin Peanut - Drug Profile 148
Trichuris Suis Ova - Drug Profile 150
Cat-PAD - Drug Profile 151
gpASIT + [TM] - Drug Profile 153
conestat alfa - Drug Profile 155
conestat alfa - Drug Profile 157
RQ-00000008 - Drug Profile 159
Peanut Allergen Vaccine - Drug Profile 205
EDP-14 - Drug Profile 206
JDP-205 - Drug Profile 208
TRI-046 - Drug Profile 239
Allergies Therapeutics - Drug Profile Updates 240
Allergies Therapeutics - Discontinued Products 272
Allergies Therapeutics - Dormant Products 273
Allergies - Product Development Milestones 277
Featured News and Press Releases 277
Appendix 284
Methodology 284
Coverage 284
Secondary Research 284
Primary Research 284
Expert Panel Validation 284
Contact Us 285
Disclaimer 285



List of Tables

Number of Products Under Development for Allergies, H1 2013 19
Products under Development for Allergies - Comparative Analysis, H1 2013 20
Number of Products under Development by Companies, H1 2013 22
Number of Products under Development by Companies, H1 2013 (Contd..1) 23
Number of Products under Development by Companies, H1 2013 (Contd..2) 24
Number of Products under Development by Companies, H1 2013 (Contd..3) 25
Number of Products under Development by Companies, H1 2013 (Contd..4) 26
Number of Products under Investigation by Universities/Institutes, H1 2013 27
Comparative Analysis by Late Stage Development, H1 2013 28
Comparative Analysis by Mid Clinical Stage Development, H1 2013 29
Comparative Analysis by Early Clinical Stage Development, H1 2013 30
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 31
Products under Development by Companies, H1 2013 32
Products under Development by Companies, H1 2013 (Contd..1) 33
Products under Development by Companies, H1 2013 (Contd..2) 34
Products under Development by Companies, H1 2013 (Contd..3) 35
Products under Development by Companies, H1 2013 (Contd..4) 36
Products under Development by Companies, H1 2013 (Contd..5) 37
Products under Development by Companies, H1 2013 (Contd..6) 38
Products under Development by Companies, H1 2013 (Contd..7) 39
Products under Investigation by Universities/Institutes, H1 2013 40
Alcon, Inc., H1 2013 41
Shionogi and Co., Ltd., H1 2013 42
AstraZeneca PLC, H1 2013 43
GlaxoSmithKline plc, H1 2013 44
Biotec Pharmacon ASA, H1 2013 45
Merck and Co., Inc., H1 2013 46
AbGenomics International, Inc., H1 2013 47
United Biomedical, Inc., H1 2013 48
Dainippon Sumitomo Pharma Co., Ltd., H1 2013 49
Pharming Group N.V., H1 2013 50
BioLineRx, Ltd., H1 2013 51
Novartis AG, H1 2013 52
Actelion Ltd, H1 2013 53
ALK-Abello A/S, H1 2013 54
Dyax Corp., H1 2013 55
Japan Tobacco Inc., H1 2013 56
Taiho Pharmaceutical Co., Ltd., H1 2013 57
ViroPharma Incorporated, H1 2013 58
Shire Plc, H1 2013 59
DBV Technologies, H1 2013 60
Celldex Therapeutics, Inc., H1 2013 61
Assessment by Monotherapy Products, H1 2013 107
Assessment by Combination Products, H1 2013 108
Allergies Therapeutics - Drug Profile Updates 248
Allergies Therapeutics - Discontinued Products 280
Allergies Therapeutics - Dormant Products 281
Allergies Therapeutics - Dormant Products (Contd..1) 282
Allergies Therapeutics - Dormant Products (Contd..2) 283
Allergies Therapeutics - Dormant Products (Contd..3) 284



List of Figures

Number of Products under Development for Allergies, H1 2013 19
Products under Development for Allergies - Comparative Analysis, H1 2013 20
Products under Development by Companies, H1 2013 21
Products under Investigation by Universities/Institutes, H1 2013 27
Late Stage Products, H1 2013 28
Mid Clinical Stage Products, H1 2013 29
Early Clinical Stage Products, H1 2013 30
Discovery and Pre-Clinical Stage Products, H1 2013 31
Assessment by Monotherapy Products, H1 2013 107
Assessment by Combination Products, H1 2013 108

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests,  Opport

2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Opport

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein ...

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.